United Therapeutics (UTHR) CEO Rothblatt Buys $1.3M of Stock

Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation, made a significant purchase of company shares. On June 25, 2026, Rothblatt acquired 9,500 shares at an average price of $135.42 each, bringing the total transaction value to approximately $1.29 million. This purchase was not part of a pre-planned trading program.

Insider Buying and Selling at United Therapeutics Corporation

The recent transaction by Martine Rothblatt marks another move in her ongoing involvement with United Therapeutics. On June 25, 2026, Rothblatt bought 9,500 shares at $135.42 each. Additionally, on the same day, she sold 9,500 shares at a price of $550.40, which was under a planned trading agreement. The day before, on June 24, she also executed similar transactions, buying and selling the same number of shares at slightly different prices.

United Therapeutics Corporation Stock Up 1.2%

Shares of United Therapeutics Corporation (NasdaqGS: UTHR) traded near $540.87 on Saturday. The company, which specializes in developing treatments for chronic and life-threatening diseases, has a market capitalization of about $23.03 billion. United Therapeutics carries a P/E ratio of 20.05 and a forward P/E of 17.08, reflecting investor expectations for future earnings. The stock's 52-week range spans from $272.12 to $609.35, with a 50-day moving average of $562.17 and a 200-day moving average of $501.21. The company maintains a strong liquidity position with a current ratio of 4.79 and a quick ratio of 4.12.

Other Institutional Activity in United Therapeutics

Several institutional investors have also adjusted their positions in United Therapeutics. BlackRock, Inc. boosted its holdings by 228,883 shares, ending with 5,399,649 shares valued at approximately $3.20 billion, a 4.4% increase. Avoro Capital Advisors LLC modestly increased its stake by 23,940 shares to a total of 2,630,000 shares worth about $1.56 billion. Conversely, Wellington Management Group LLP reduced its position by 177,245 shares, leaving it with 2,264,247 shares valued at $1.34 billion, a 7.3% decrease. Both Vanguard Portfolio Management LLC and Vanguard Capital Management LLC opened new positions with substantial share counts.

Analysts Set New Price Targets

Analysts have been active in updating their views on United Therapeutics. On May 7, 2026, RBC Capital maintained its 'buy' rating with a price target of $701. Wells Fargo upgraded the stock to a 'buy' with a target of $738 on the same day. Earlier in April, Morgan Stanley maintained a 'hold' rating with a target of $519. The consensus among 13 analysts suggests a 'buy' recommendation, with a mean price target of $665.23.

About United Therapeutics

United Therapeutics Corporation, headquartered in Silver Spring, Maryland, is a healthcare company that develops and commercializes treatments for chronic and life-threatening conditions. The company focuses on pulmonary arterial hypertension (PAH) and other severe diseases, offering products like Tyvaso DPI, Remodulin, Orenitram, and Adcirca. Led by CEO Dr. Martine A. Rothblatt, United Therapeutics is also involved in cutting-edge research in xenotransplantation and regenerative medicine, employing around 1,400 people.

Bottom Line

Martine Rothblatt's recent purchase of United Therapeutics shares underscores her confidence in the company's future. Investors keep a close eye on insider transactions as they can provide insights into the company's prospects. United Therapeutics, with its solid financial metrics and innovative healthcare solutions, continues to be a key player in the biotech sector. As always, remember that insider transactions are disclosed after the fact and may not reflect current holdings.